Biosimilar Filgrastim Uptake And Costs Among Commercially Insured, Medicare Advantage

Pinar Karaca-Mandic; Jessica Chang; Ronald Go; Stephen Schondelmeyer; Daniel Weisdorf; Molly Moore Jeffery

doi:10.1377/hlthaff.2019.00253

Biosimilar Filgrastim Uptake And Costs Among Commercially Insured, Medicare Advantage

Pinar Karaca-Mandic, Jessica Chang, Ronald Go, Stephen Schondelmeyer, Daniel Weisdorf, Molly Moore Jeffery

Research output: Contribution to journal › Article › peer-review

17 Scopus citations

Abstract

In 2015 the Food and Drug Administration approved filgrastim-sndz (Zarxio), the first US biosimilar. Following rapid uptake, by March 2018 filgrastim-sndz accounted for 47 percent of filgrastim administrations among commercially insured and 42 percent among Medicare Advantage beneficiaries. The initial cost difference between the originator and biosimilar was 31 percent in the former population but negligible in the latter.

Original language	English (US)
Pages (from-to)	1887-1892
Number of pages	6
Journal	Health affairs (Project Hope)
Volume	38
Issue number	11
DOIs	https://doi.org/10.1377/hlthaff.2019.00253
State	Published - Nov 1 2019

Keywords

Biologics
Biosimilar
Biosimilars
Cost reduction
FDA approvals process
Filgrastim-sndz
Health policy
Medicare Advantage
Out-of-pocket expenses
Pharmaceuticals
Prescription drug costs
Zarxio

PubMed: MeSH publication types

Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

Access

10.1377/hlthaff.2019.00253

OpenUrl availability

Full text

Cite this

@article{7bf035225a764f5dacd3fb003dc0a28b,

title = "Biosimilar Filgrastim Uptake And Costs Among Commercially Insured, Medicare Advantage",

abstract = "In 2015 the Food and Drug Administration approved filgrastim-sndz (Zarxio), the first US biosimilar. Following rapid uptake, by March 2018 filgrastim-sndz accounted for 47 percent of filgrastim administrations among commercially insured and 42 percent among Medicare Advantage beneficiaries. The initial cost difference between the originator and biosimilar was 31 percent in the former population but negligible in the latter.",

keywords = "Biologics, Biosimilar, Biosimilars, Cost reduction, FDA approvals process, Filgrastim-sndz, Health policy, Medicare Advantage, Out-of-pocket expenses, Pharmaceuticals, Prescription drug costs, Zarxio",

author = "Pinar Karaca-Mandic and Jessica Chang and Ronald Go and Stephen Schondelmeyer and Daniel Weisdorf and Jeffery, {Molly Moore}",

year = "2019",

month = nov,

day = "1",

doi = "10.1377/hlthaff.2019.00253",

language = "English (US)",

volume = "38",

pages = "1887--1892",

journal = "Health affairs (Project Hope)",

issn = "0278-2715",

publisher = "Project Hope",

number = "11",

}

TY - JOUR

T1 - Biosimilar Filgrastim Uptake And Costs Among Commercially Insured, Medicare Advantage

AU - Karaca-Mandic, Pinar

AU - Chang, Jessica

AU - Go, Ronald

AU - Schondelmeyer, Stephen

AU - Weisdorf, Daniel

AU - Jeffery, Molly Moore

PY - 2019/11/1

Y1 - 2019/11/1

N2 - In 2015 the Food and Drug Administration approved filgrastim-sndz (Zarxio), the first US biosimilar. Following rapid uptake, by March 2018 filgrastim-sndz accounted for 47 percent of filgrastim administrations among commercially insured and 42 percent among Medicare Advantage beneficiaries. The initial cost difference between the originator and biosimilar was 31 percent in the former population but negligible in the latter.

AB - In 2015 the Food and Drug Administration approved filgrastim-sndz (Zarxio), the first US biosimilar. Following rapid uptake, by March 2018 filgrastim-sndz accounted for 47 percent of filgrastim administrations among commercially insured and 42 percent among Medicare Advantage beneficiaries. The initial cost difference between the originator and biosimilar was 31 percent in the former population but negligible in the latter.

KW - Biologics

KW - Biosimilar

KW - Biosimilars

KW - Cost reduction

KW - FDA approvals process

KW - Filgrastim-sndz

KW - Health policy

KW - Medicare Advantage

KW - Out-of-pocket expenses

KW - Pharmaceuticals

KW - Prescription drug costs

KW - Zarxio

UR - http://www.scopus.com/inward/record.url?scp=85074548046&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074548046&partnerID=8YFLogxK

U2 - 10.1377/hlthaff.2019.00253

DO - 10.1377/hlthaff.2019.00253

M3 - Article

C2 - 31682491

SN - 0278-2715

VL - 38

SP - 1887

EP - 1892

JO - Health affairs (Project Hope)

JF - Health affairs (Project Hope)

IS - 11

ER -

Biosimilar Filgrastim Uptake And Costs Among Commercially Insured, Medicare Advantage

Abstract

Keywords

PubMed: MeSH publication types

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this